Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs
MWN-AI** Summary
Adagene Inc. has announced the pricing of its public offering, aiming to raise approximately $70.0 million through the sale of 18,666,000 American depositary shares (ADSs) at an offering price of $3.75 per ADS, which reflects the 30-day volume-weighted average price (VWAP). Each ADS represents 1.25 ordinary shares of the company. The closure of the offering is anticipated on April 6, 2026, pending the fulfillment of standard closing conditions.
The offering features participation from both new and existing investors, including notable names such as Janus Henderson Investors, Deerfield Management, Invus, Sirenia, and Columbia Threadneedle Investments. Leerink Partners and LifeSci Capital are acting as joint book-running managers, assisted by Lucid Capital Markets as a co-manager. This public offering is registered under a shelf registration statement filed with the Securities and Exchange Commission (SEC) in May 2025, with a corresponding prospectus supplement expected to be available on the SEC’s website.
Adagene Inc. is a clinical-stage biotechnology company focusing on the research and development of antibody-based therapies, specifically targeting cancer immunotherapy. The company leverages computational biology and artificial intelligence to create novel antibodies addressing unmet medical needs. Its innovative SAFEbody precision masking technology has led to strategic collaborations with leading global partners, positioning Adagene at the forefront of scientific advancements in treatment approaches.
Investors are cautioned that forward-looking statements in the release involve risks and uncertainties, particularly regarding closing conditions and market dynamics that could affect actual outcomes. Adagene has committed to updating investors as required by law while acknowledging the inherent uncertainties in their forward-looking claims.
MWN-AI** Analysis
Adagene Inc.'s recent announcement regarding its public offering of American Depositary Shares (ADSs) at a price of $3.75 each, aiming to raise approximately $70 million, presents both opportunity and caution for investors. The successful pricing at the volume-weighted average price (VWAP) suggests robust demand among existing and new investors, including notable participants like Janus Henderson Investors and Deerfield Management. Such interest reflects confidence in Adagene's innovative approach in the competitive field of antibody-based therapies.
Investors should consider several factors before participating in or adjusting their position in ADAG shares. The expected net proceeds will likely be directed towards advancing clinical trials and expanding Adagene’s SAFEbody platform, which is crucial for maintaining its competitive edge. The advancement of its pipeline is pivotal, particularly in a sector characterized by rapid innovation and significant capital requirements.
However, potential investors should remain vigilant about several risks outlined in the company’s filings. The biotechnology sector is notoriously volatile, heavily influenced by regulatory outcomes, clinical trial results, and market conditions. The reliance on technology and partnerships increases exposure to development risks; thus, the successful execution of its strategic collaborations is essential for long-term growth.
Furthermore, the issuance of new shares could dilute existing shareholder value, which is a key consideration for current investors. If the shares perform favorably post-offering and clinical advancements continue, it could bolster investor confidence and provide a price appreciation opportunity.
In summary, while Adagene’s offering presents a moment of strategic growth, investors must weigh the prospects against the inherent risks of the biotechnology industry. It may be prudent to adopt a cautious approach, monitoring market trends and company developments closely before making investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
SAN DIEGO and SUZHOU, China, April 02, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene” or the “Company”) (Nasdaq: ADAG), a company committed to transforming the discovery and development of novel antibody-based therapies, today announced the pricing of its underwritten public offering of 18,666,000 American depositary shares, or ADSs, each representing 1.25 ordinary shares of the Company, par value US$0.0001 per share, at the offering price of US$3.75 per ADS, representing the 30-day volume-weighted average price (“VWAP”).
The gross proceeds to Adagene from the offering are expected to be approximately US$70.0 million, before deducting underwriting discount and offering expenses. The offering is expected to close on April 6, 2026, subject to the satisfaction of customary closing conditions.
Leerink Partners and LifeSci Capital are acting as joint book-running managers for the offering. Lucid Capital Markets is acting as co-manager for the offering.
The offering featured participation from new and existing investors including Janus Henderson Investors, Deerfield Management, Invus, Sirenia and Columbia Threadneedle Investments, among others.
The offering is being made pursuant to a shelf registration statement on Form F-3, including a base prospectus, that was initially filed with the Securities and Exchange Commission (SEC) on May 9, 2025 and became effective on May 30, 2025. A prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available for free on the SEC’s website located at www.sec.gov. Copies of the prospectus relating to the offering may be obtained, when available, from: Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109, by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@leerink.com; or LifeSci Capital LLC, 1700 Broadway, 40th Floor, New York, New York 10019, or by email at legalnotices@lifescicapital.com.
This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Adagene Inc.
Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address globally unmet patient needs. The company has forged strategic collaborations with reputable global partners that leverage its SAFEbody precision masking technology in multiple approaches at the vanguard of science.
Safe Harbor Statement
This press release contains forward-looking statements, including, but not limited to, statements relating to the satisfaction of customary closing conditions related to the offering, the expected closing of the offering and the anticipated gross proceeds from the offering and Adagene’s intended use of the net proceeds therefrom. Actual results may differ materially from those indicated in the forward-looking statements due to the risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the offering, as well as risks and uncertainties inherent in Adagene’s business described in the Company’s prior press releases as well as those risks more fully discussed in the “Risk Factors” section in Adagene’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Adagene, and Adagene undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.
Investor Contacts:
Raymond Tam
raymond_tam@adagene.com
Corey Davis
LifeSci Advisors
cdavis@lifesciadvisors.com
Media Contact:
Lindsay Rocco
Elixir Health PR
862-596-1304
lrocco@elixirhealthpr.com
FAQ**
How might the successful public offering of Adagene Inc. ADAG impact biotechnology investments in cities like San Diego compared to Suzhou, China, known for its growing tech and biotech sectors?
What potential collaborations could arise between biotech firms in San Diego and Suzhou, China, following Adagene Inc. ADAG's recent funding announcement aimed at antibody-based therapies?
Considering the strategies employed by Adagene Inc. ADAG, how do you envision the landscape of antibody-based therapies evolving in both San Diego and Suzhou, China, in the next five years?
In what ways could the market reactions to Adagene Inc. ADAG's funding influence investor sentiment in the biotech sectors of San Diego and Suzhou, China, particularly regarding future investment opportunities?
**MWN-AI FAQ is based on asking OpenAI questions about Adagene Inc. (NASDAQ: ADAG).
NASDAQ: ADAG
ADAG Trading
-7.35% G/L:
$3.31 Last:
10,335 Volume:
$3.56 Open:
